XtalPi, a leader in AI-powered drug discovery, and Parthenon Therapeutics, a clinical-stage biotech company focused on reprogramming the tumor microenvironment, have announced a collaboration to discover novel therapeutic antibodies for treating solid tumors.
XtalPi will provide Parthenon Therapeutics with access to its XupremAb™ antibody discovery platform, which combines AI and wet lab techniques to develop therapeutic antibody candidates with enhanced efficacy and developability profiles.
The two companies will employ various approaches within the XupremAb™ platform to explore the immune repertoire and create a comprehensive dataset, which XtalPi's proprietary algorithms will analyse for outstanding candidates.
This collaboration aims to advance the development of next-generation cancer therapeutics by combining Parthenon Therapeutics’ expertise in tumour barrier disruption with XtalPi's AI-powered antibody discovery platform.
Click here to read the original news story.